Geneva, July 31, 2014

2014 HALF-YEAR PRESS RELEASE

Activity

Revenues for the first six months of the year grew 12% compared to 1H2013, in line with management expectations.

Direct sales revenues grew 47% thanks to the contribution of new German and Spanish direct sales subsidiaries. Excluding Germany and Spain, direct sales revenues grew 9%. Sales in the US grew 23% in constant currency.

International sales to distributors (excluding former German and Spanish distributors) decreased 16%.

In April 2014 Spineart finalised the acquisition of Ortomedimatec Spanish distribution activities related to spinal and cranial surgery. In June 2014 Spineart secured $15.5 million of new financing from new equity and credit facilities.

During the first part of the year, Spineart hosted various national and international bioskills labs. These sessions focused on Spineart's state-of-the-art technology platforms in motion, deformity and MIS.

The distribution of Spineart products was initiated in Saudi Arabia, Hungary and Slovakia.

Technology Platforms

Spineart announced the excellent results of a prospective observational study showing the safety and effectiveness at 2 years post surgery of the BAGUERA® C cervical disc prosthesis. These results will be presented during the 2014 NASS meeting in San Francisco in November.

Spineart successfully completed a limited release OUS of its new titanium secured cervical cage, SCARLET®AC-T. This implant is currently pending FDA approval in the US.

The international adoption of ROMEO®2 PAD, Spineart's MIS Posterior Axial Fusion Device, continues with more than 1,800 surgeries already reported. This implant is currently pending FDA approval in the US.

During the first part of 2014, Spineart received approval from the FDA for its JULIET®LL lateral cages, JULIET®OL extra lordotic cages and ROMEO®2 cortical screws.

In March 2014, TRYPTIK®CA, TRYPTIK®MC and ROMEO®2 MS received approval from the Chinese CFDA.

Limited product release for the Company's novel system for the treatment of Vertebral Compression Fractures continues with the addition of two university centers in Italy and Germany to the two French university centers already involved.

Limited product release was also initiated in Europe for Spineart's new ROMEO® fenestrated screws as well as its unique radiolucent carbon fiber retractor OTELO®PO associated with its MIS platform.

Prospects

For the second part of 2014, Spineart is anticipating continued double-digit growth backed by the continued expansion of its product portfolio and strengthening of its sales network.

About Spineart

Spineart is a privately held medical device company focused on simplifying the surgical act by designing, developing and promoting safe and efficient solutions to spine surgeons, operating room teams, and patients.

Spineart is a pioneer in its field, having introduced unique patented and clinically validated technologies in the fields of Minimally Invasive Surgery, Motion Preservation, Fusion, Biologics, and Fractures Treatment.

Spineart markets a complete portfolio combining traceable barcoded sterile packed implants with compact instrument sets, thus proudly promoting greater safety, cost-efficiency, and compliance at the hospital.

For more information please contact us at contact@spineart.com or visit spineart.com.